Terms: = Head and neck cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
40 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer.
Kawasaki K; Noma K; Kato T; Ohara T; Tanabe S; Takeda Y; Matsumoto H; Nishimura S; Kunitomo T; Akai M; Kobayashi T; Nishiwaki N; Kashima H; Maeda N; Kikuchi S; Tazawa H; Shirakawa Y; Fujiwara T
Cancer Immunol Immunother; 2023 Nov; 72(11):3787-3802. PubMed ID: 37668710
[TBL] [Abstract] [Full Text] [Related]
3. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
4. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF; Steuer CE; Ekpenyong A; McCook-Veal A; Magliocca K; Patel M; Schmitt NC; Stokes W; Bates JE; Rudra S; Remick J; McDonald M; Abousaud M; Tan AC; Fadlullah MZH; Chaudhary R; Muzaffar J; Kirtane K; Liu Y; Chen GZ; Shin DM; Teng Y; Chung CH
Nat Med; 2023 Apr; 29(4):880-887. PubMed ID: 37012550
[TBL] [Abstract] [Full Text] [Related]
5. The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
Mühlenbruch L; Abou-Kors T; Dubbelaar ML; Bichmann L; Kohlbacher O; Bens M; Thomas J; Ezić J; Kraus JM; Kestler HA; von Witzleben A; Mytilineos J; Fürst D; Engelhardt D; Doescher J; Greve J; Schuler PJ; Theodoraki MN; Brunner C; Hoffmann TK; Rammensee HG; Walz JS; Laban S
Br J Cancer; 2023 May; 128(9):1777-1787. PubMed ID: 36823366
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic significance of pd-1, CTLA-4, CD4, and CD8 expression in olfactory neuroblastoma.
Wu L; Liu H; Liu H
Clin Neuropathol; 2023; 42(2):47-53. PubMed ID: 36708210
[TBL] [Abstract] [Full Text] [Related]
7. TMPRSS4 is a novel biomarker and correlated with immune infiltration in thyroid carcinoma.
Xu X; Sun T; Jing J
BMC Endocr Disord; 2022 Nov; 22(1):280. PubMed ID: 36380313
[TBL] [Abstract] [Full Text] [Related]
8. Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-pd-1 therapy.
Xie W; Zeng Y; Hu L; Hao J; Chen Y; Yun X; Lin Q; Li H
Front Immunol; 2022; 13():991656. PubMed ID: 36211409
[TBL] [Abstract] [Full Text] [Related]
9. Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer.
Bell RB; Gough M; Crittenden M; Young K
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 36106641
[TBL] [Abstract] [Full Text] [Related]
10. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal cancer Treated With Combined Chemoradiotherapy and pd-1 Blockade.
Ma X; Guo Z; Wei X; Zhao G; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao L; Yuan Z; Wang P; Pang Q; Yan C; Zhang W
Front Immunol; 2021; 12():786429. PubMed ID: 35046943
[TBL] [Abstract] [Full Text] [Related]
11. DNA Vaccines Targeting Novel cancer-Associated Antigens Frequently Expressed in head and neck cancer Enhance the Efficacy of Checkpoint Inhibitor.
Wang C; Zainal NS; Chai SJ; Dickie J; Gan CP; Zulaziz N; Lye BKW; Sutavani RV; Ottensmeier CH; King EV; Abraham MT; Ismail SMB; Lau SH; Kallarakkal TG; Mun KS; Zain RB; Abdul Rahman ZA; Thomas GJ; Cheong SC; Savelyeva N; Lim KP
Front Immunol; 2021; 12():763086. PubMed ID: 34733290
[TBL] [Abstract] [Full Text] [Related]
12. Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in head and neck Squamous Cell Carcinoma.
Wang X; Cao K; Guo E; Mao X; Guo L; Zhang C; Guo J; Wang G; Yang X; Sun J; Miao S
Front Immunol; 2021; 12():658631. PubMed ID: 33995377
[TBL] [Abstract] [Full Text] [Related]
13. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic head and neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Features of cancer-associated Fibroblast Subtypes and their Implication on cancer Pathogenesis, Prognosis, and Immunotherapy Resistance.
Galbo PM; Zang X; Zheng D
Clin Cancer Res; 2021 May; 27(9):2636-2647. PubMed ID: 33622705
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Impact of pd-1 on Tumor-Infiltrating Lymphocytes in 433 Resected Esophageal cancers.
Nomoto D; Baba Y; Okadome K; Yagi T; Kalikawe R; Kiyozumi Y; Harada K; Eto K; Hiyoshi Y; Nagai Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Watanabe M; Baba H
Ann Thorac Surg; 2022 Jan; 113(1):286-294. PubMed ID: 33482156
[TBL] [Abstract] [Full Text] [Related]
16. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract] [Full Text] [Related]
17. Hypoxia dynamics on FMISO-PET in combination with pd-1/PD-L1 expression has an impact on the clinical outcome of patients with head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract] [Full Text] [Related]
18. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract] [Full Text] [Related]
19. The Latest Findings of pd-1/PD-L1 Inhibitor Application in Gynecologic cancers.
Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
[TBL] [Abstract] [Full Text] [Related]
20. Anti-pd-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
[Next]
